Chemoimmunotherapy in urothelial cancer: concurrent or sequential?
https://doi.org/10.17650/1726-9776-2021-17-4-124-128
Abstract
Advances in immuno-oncology in the treatment of metastatic urothelial cancer have overturned current perspectives on the treatment of this type of tumor. The success of using Immune checkpoint inhibitors in metastatic urothelial cancer raised the question of effectiveness of immunotherapy added to standard first-line chemotherapy. This review presents data coming from actual studies examining chemotherapy and immunotherapy in urothelial cancer, or a combination of these methods. Ongoing and planned clinical studies should help identify the optimal sequencing, feasibility of combination, and best duration of treatment with checkpoint inhibitors in urothelial cancer.
About the Authors
A. Yu. Pavlov
Russian Scientific Center of Roentgen Radiology, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
86 Profsoyuznaya St., Moscow 117997.
Competing Interests:
The authors declare no conflict of interest.
A. G. Dzidzariya
Russian Scientific Center of Roentgen Radiology, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
86 Profsoyuznaya St., Moscow 117997.
Competing Interests:
The authors declare no conflict of interest.
R. A. Gafanov
Russian Scientific Center of Roentgen Radiology, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
Rustem Ayratovich Gafanov.
86 Profsoyuznaya St., Moscow 117997.
Competing Interests:
The authors declare no conflict of interest.
I. I. Khalil'
Russian Scientific Center of Roentgen Radiology, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
86 Profsoyuznaya St., Moscow 117997.
Competing Interests:
The authors declare no conflict of interest.
A. R. Vashurin
Russian Scientific Center of Roentgen Radiology, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
86 Profsoyuznaya St., Moscow 117997.
Competing Interests:
The authors declare no conflict of interest.
References
1. Powles T., Csoszi T., Ozguroglu M. et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol 2021;22(7):931-45. DOI: 10.1016/S1470-2045(21)00152-2.
2. Galsky M.D., Arija J.A.A., Bamias A. et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2020;395(10236):1547-57. DOI: 10.1016/S0140-6736(20)30230-0.
3. Galsky M.D., Arija J.A.A., Grande E. et al. Atezolizumab + platinum/gemcitabine vs placebo + platinum/gemcitabine in patients with previously untreated locally advanced or metastatic urothelial carcinoma: updated overall survival from the randomized phase III study IMvigor130. AACR Annual Meeting 2021;81(13). DOI: 10.1158/1538-7445.AM2021-CT042.
4. Grande E., Bamias A., Galsky M.D., Kikuchi E. Overall survival (OS) by response during “induction” from the global, randomized Phase III IMvigor130 study of atezolizumab (atezo) + platinum/ gemcitabine (plt/gem) vs placebo + plt/ gem in patients (pts) with previously untreated metastatic urothelial carcinoma (mUC). AACR Annual Meeting 2021. DOI: 10.1158/1538-7445.AM2021-CT187.
5. Davis I.D., Galsky M.D., del Muro X.G. et al. Updated overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (mUC) in IMvigor130. AACR Annual Meeting 2021;81(13). DOI: 10.1158/1538-7445.AM2021-CT040.
6. Powles T., Park S.H., Voog E. et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 2020;383(13): 1218-30. DOI: 10.1056/NEJMoa2002788.
7. Loriot Y., Duran M.A.C., Powles T., Sridhar S.S. Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy. J Clin Oncol 2021;39(6_suppl):438. DOI: 10.1200/JCO.2021.39.6_suppl.438.
8. Seiler R., Ashab H.A.D., Erho N. et al. Impact of molecular subtypes in musclein-vasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol 2017;72(4):544-54. DOI: 10.1016/j.eururo.2017.03.030.
9. Khaki A.R., Li A., Diamantopoulos L.N. et al. A new prognostic model in patients with advanced urothelial carcinoma treated with first-line immune checkpoint inhibitors. Eur Urol Oncol 2021;4(3):464-72. DOI: 10.1016/j.euo.2020.12.006.
10. Sharma P., Retz M., Siefker-Radtke A. et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2017;18(3):312-22. DOI: 10.1016/S1470-2045(17)30065-7.
11. Emens L.A., Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res 2015;3(5):436-43. DOI: 10.1158/2326-6066.CIR-15-0064.
12. Bailly C., Thuru X., Quesnel B. Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times. NAR Cancer 2020;2(1):zcaa002. DOI: 10.1093/narcan/zcaa002.
13. Bajorin D.F., Witjes J.A., Gschwend J., Schenker M. First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC). J Clin Oncol 2021;39(6_suppl):391. DOI: 10.1200/JCO.2021.39.6_suppl.391.
Review
For citations:
Pavlov A.Yu., Dzidzariya A.G., Gafanov R.A., Khalil' I.I., Vashurin A.R. Chemoimmunotherapy in urothelial cancer: concurrent or sequential? Cancer Urology. 2021;17(4):124-128. (In Russ.) https://doi.org/10.17650/1726-9776-2021-17-4-124-128
Views:
509
Email this article 